279 related articles for article (PubMed ID: 22356677)
1. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
2. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.
Slipicevic A; Jørgensen K; Skrede M; Rosnes AK; Trøen G; Davidson B; Flørenes VA
BMC Cancer; 2008 Sep; 8():276. PubMed ID: 18826602
[TBL] [Abstract][Full Text] [Related]
3. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.
Li J; Cheng Y; Tai D; Martinka M; Welch DR; Li G
Oncogene; 2011 Feb; 30(8):896-906. PubMed ID: 20935672
[TBL] [Abstract][Full Text] [Related]
5. Location, location, location: the BRMS1 protein and melanoma progression.
Riker AI; Samant RS
BMC Med; 2012 Feb; 10():19. PubMed ID: 22356729
[TBL] [Abstract][Full Text] [Related]
6. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
Jørgensen K; Davidson B; Flørenes VA
Mod Pathol; 2006 Nov; 19(11):1446-55. PubMed ID: 16951673
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
8. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
9. A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.
Frolova N; Edmonds MD; Bodenstine TM; Seitz R; Johnson MR; Feng R; Welch DR; Frost AR
Tumour Biol; 2009; 30(3):148-59. PubMed ID: 19609101
[TBL] [Abstract][Full Text] [Related]
10. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Screaton G; Hersey P
Hum Pathol; 2006 Oct; 37(10):1286-94. PubMed ID: 16949935
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
12. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Flørenes VA; Maelandsmo GM; Kerbel RS; Slingerland JM; Nesland JM; Holm R
Am J Pathol; 1998 Jul; 153(1):305-12. PubMed ID: 9665492
[TBL] [Abstract][Full Text] [Related]
13. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.
Garrido-Ruiz MC; Rodriguez-Pinilla SM; Pérez-Gómez B; Rodriguez-Peralto JL
J Cutan Pathol; 2010 May; 37(5):542-8. PubMed ID: 19638168
[TBL] [Abstract][Full Text] [Related]
14. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
15. Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.
Flørenes VA; Emilsen E; Dong HP; Førsund M; Holm R; Slipicevic A
Cancer Med; 2015 Jun; 4(6):903-13. PubMed ID: 25663244
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
Zhang S; Lin QD; DI W
Int J Gynecol Cancer; 2006; 16(2):522-31. PubMed ID: 16681721
[TBL] [Abstract][Full Text] [Related]
18. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
19. Maspin expression and melanoma progression: a matter of sub-cellular localization.
Martinoli C; Gandini S; Luise C; Mazzarol G; Confalonieri S; Giuseppe Pelicci P; Testori A; Ferrucci PF
Mod Pathol; 2014 Mar; 27(3):412-9. PubMed ID: 24030740
[TBL] [Abstract][Full Text] [Related]
20. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]